Botulinum Toxin A: Evolving Treatment Strategies for the Chronic Pelvic Pain Patient

被引：0
作者：
Smith W.R. [1 ]
Murphy A.M. [1 ]
Das A.K. [1 ]
Shenot P.J. [1 ]
机构：
[1] Department of Urology, Thomas Jefferson University, 1025 Walnut Street Suite 1100, Philadelphia, 19107, PA
来源：
Current Bladder Dysfunction Reports | 2016年 / 11卷 / 3期
关键词：
Botulinum toxin; Chronic pain; Chronic pelvic pain syndrome (CPPS); Pelvic pain;
D O I：
10.1007/s11884-016-0374-3
中图分类号：
学科分类号：
摘要：
Chronic pelvic pain syndrome (CPPS) is defined as pain perceived within the structures of the male or female pelvis of at least 6-month duration. The management of CPPS in both men and women poses a challenge to both the clinician and the patient. Botulinum toxin type A (BoNT-A) is known to block the release of neurotransmitters at the neuromuscular junction but also appears to have anti-nociceptive and anti-inflammatory effects. BoNT-A has been used for over two decades to treat conditions associated with pathological muscle hyperactivity. There is emerging evidence that BoNT-A may play a role in treating CPPS when alternate treatments and more conservative measures have been ineffective. Moving forward, well-designed clinical trials are needed to further investigate the utility of BoNT-A use in the treatment of CPPS. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：277 / 283
页数：6
相关论文
共 33 条
[1]  
Fall M., Baranowski A.P., Fowler C.J., Lepinard V., Malone-Lee J.G., Messelink E.J., Et al., EAU guidelines on chronic pelvic pain, Eur Urol, 46, pp. 681-689, (2004)
[2]  
Moldwin R.M., Similarities between interstitial cystitis and male chronic pelvic pain syndrome, Curr Urol Rep, 3, pp. 313-318, (2002)
[3]  
Pontari M.A., Chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: are they related?, Curr Urol Rep, 7, pp. 329-334, (2006)
[4]  
Dolly J.O., Aoki K.R., The structure and mode of action of different botulinum toxins, Eur J Neurol, 13, pp. 1-9, (2006)
[5]  
Mangera A., Andersson K.E., Apostolidis A., Chapple C., Dasgupta P., Giannantoni A., Et al., Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA), Eur Urol, 60, pp. 784-795, (2011)
[6]  
Apostolidis A., Dasgupta P., Fowler C.J., Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity, Eur Urol, 49, pp. 644-650, (2006)
[7]  
Chuang Y.C., Yoshimura N., Wu M., Huang C.C., Chiang P.H., Tyagi P., Et al., Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A, Eur Urol, 51, pp. 1119-1127, (2007)
[8]  
Jhang J.F., Kuo H.C., Novel treatment of chronic bladder pain syndrome and other pelvic pain disorders by onabotulinumtoxinA injection, Toxins (Basel), 7, 6, pp. 2232-2250, (2015)
[9]  
Hanno P.M., Erickson D., Moldwin R., Farday M.M., American Urological Association, Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment, J Urol, 193, 5, pp. 1545-1553, (2015)
[10]  
Konkle K.S., Berry S.H., Elliott M.N., Hilton L., Suttorp M.J., Clauw D.J., Et al., Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study, J Urol, 187, 2, pp. 508-512, (2012)
1234